# Tuberculosis prevention in children, adolescents, and pregnant and postpartum women in South Africa

**Authors:** Mareike Rabe, Jennifer A. Hughes

PMC · DOI: 10.4102/safp.v68i1.6198 · South African Family Practice · 2026-01-16

## TL;DR

The paper discusses strategies to prevent tuberculosis in vulnerable groups in South Africa, emphasizing a comprehensive approach including vaccines and therapies.

## Contribution

It introduces a multipronged prevention framework tailored for children, adolescents, and pregnant/postpartum women.

## Key findings

- Pharmacological interventions like BCG vaccination and TB preventive therapy regimens are reviewed for CAPPW.
- The paper highlights the importance of combining infection control with psychosocial and nutritional support.
- It provides evidence-based recommendations for TPT regimens and their safety in vulnerable populations.

## Abstract

Tuberculosis (TB), particularly drug-resistant TB (DR-TB), remains a major public health concern in South Africa (SA), with children, adolescents, and pregnant and postpartum women (CAPPW) facing heightened risks because of biological and social vulnerabilities. This article highlights the importance of a multipronged prevention framework that combines infection control measures, psychosocial support, education, and nutritional supplementation, alongside pharmacological interventions such as Bacillus Calmette-Guérin (BCG) vaccination and tailored TB preventive therapy (TPT). Drawing on national guidelines and recent academic literature, the article provides an overview of current evidence and recommendations for TPT regimens (including 6H, 3HP, 3RH, 4R, 12H, and 6LFX) and their eligibility, safety considerations, drug interactions, and formulations suitable for CAPPW. By strengthening awareness and streamlining guideline-based prevention efforts, the article equips healthcare workers to make informed, patient-centred decisions to improve treatment outcomes and ultimately reduce TB transmission in high-burden settings.

## Linked entities

- **Diseases:** tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, UGT1A1 (UDP glucuronosyltransferase family 1 member A1) [NCBI Gene 54658] {aka BILIQTL1, GNT1, HUG-BR1, UDPGT, UDPGT 1-1, UGT1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** silicosis (MESH:D012829), liver dysfunction (MESH:D017093), pulmonary TB (MESH:D014397), infected (MESH:D007239), pulmonary and extrapulmonary TB disease (MESH:D000092225), peripheral neuropathy (MESH:D010523), Bleeding (MESH:D006470), HIV/TB (MESH:D014376), toxicities (MESH:D064420), use (MESH:D019966), HIV (MESH:D015658), malnutrition (MESH:D044342), DS-TB disease (MESH:D004198), (cavitary) pulmonary disease (MESH:D008171), -resistant (DR)-TB (MESH:D018088)
- **Chemicals:** Vitamin K (MESH:D014812), PIs (MESH:D010716), fluoroquinolone (MESH:D024841), pyridoxine (MESH:D011736), vitamin B6 (MESH:D025101), TDF (MESH:D000068698), lopinavir-ritonavir (MESH:C558899), EFV (MESH:C098320), Isoniazid (MESH:D007538), 6H (-), NVP (MESH:D019829), raltegravir (MESH:D000068898), DTG (MESH:C562325), Rifampicin (MESH:D012293), rifamycin (MESH:C023808), rifapentine (MESH:C018421), levofloxacin (MESH:D064704), delamanid (MESH:C516022)
- **Species:** Mycobacterium tuberculosis variant bovis BCG (no rank) [taxon 33892], Human immunodeficiency virus 1 (no rank) [taxon 11676], Human immunodeficiency virus (species) [taxon 12721], Bacillus sp. CG (species) [taxon 1196795], Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12869830/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12869830/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12869830/full.md

---
Source: https://tomesphere.com/paper/PMC12869830